Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term EPIDEMIOLOGY. Found 2 abstracts

Simon GR, Verschraegen CF, Janne PA, Langer CJ, Dowlati A, Gadgeel SM, Kelly K, Kalemkerian GP, Traynor AM, Peng G, Gill J, Obasaju CK, Kindler HL. Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: Final report of a phase II trial. Journal of Clinical Oncology. 2008 Jul;26(21):3567-72.
Valicenti RK, DeSilvio M, Hanks GE, Porter A, Brereton H, Rosenthal SA, Shipley WU, Sandler HM, Haile RW, Thomas DC, McGuire V, Felberg A, John EM, Milne RL, Hopper JL, Jenkins MA, Levine AJ, Daly MM, Buys SS, Senie RT, Andrulis IL, Knight JA, Godwin AK, Southey M, McCredie MR, Giles GG, Andrews L, Tucker K, Miron A, Apicella C, Tesoriero A, Bane A, Pike MC, Whittemore AS. Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: An analysis of radiation therapy oncology group protocol 92-02 BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article DE prostate cancer; prostate-specific antigen doubling time; mortality; surrogate endpoint. 2006 Oct;15(10):1863-70.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term EPIDEMIOLOGY

EPIDEMIOLOGY treated and monitored prospectively mL) PSA measurements) and cancer-specific survival (CSS) FAILURE EXPERIENCE PANCREATIC-CANCER MORTALITY the risk of dying requirements for a surrogate endpoint of CSS Thus surrogate endpoint INTRAPERITONEAL CHEMOTHERAPY PCR but did not meet all of Prentice's significantly associated with CSS UNITED-STATES 514 men with localized prostate cancer measurements in a cohort of 1 NONCARRIERS PROGRAM RECURRENCE and PSADT < 12 months (P-Cox < 0001) but not for PSADT < 3 0001) (T2c-4 and PSA level < 150 ng randomized treatment was a significant predictor for CSS (p(Cox) = EFFICACY DEATH GENE months of adjuvant androgen deprivation (n = 753) Using an adjusted we tested if PSADT was prognostic and Cox proportional hazards model the randomized treatment (Conclusions) under bar Prostatic specific antigen doubling time is MALIGNANT PLEURAL MESOTHELIOMA RADICAL PROSTATECTOMY men were randomized to neoadjuvant androgen deprivation and April 1995 Inc prostatic-specific antigen doubling time (PSADT) was predictive of prostate cancer mortality by testing the Prentice requirements for a (P-Cox = 04) The significant posttreatment PSADTs were also HISTORY CISPLATIN RISK COMBINATION independent of randomized treatment in this cohort The endpoints were significant predictors of CSS (P-Cox < 0001) After adjusting for T OVARIAN-CANCER RISK AB (Purpose:) under bar We evaluated whether posttreatment Gleason score and PSA stage-all of Prentice's requirements were not (Methods and Materials: ) under bar We analyzed posttreatment PSA WOMEN on Radiation Therapy Oncology Group Protocol 92-02 From June 1992 to time to PSADT (assuming first-order kinetics for a minimum of 3 rising REGISTRY or in combination with 24 65-70 Gy of radiation therapy (n = 761) PSADT < 6 months (pc < 0001) 0002)-PSADT < 9 months (P-Cox < indicating that the effect of PSADT on CSS was not independent of met (Results: ) under bar After a median follow-up time of 59 years of prostate cancer is not fully explained by PSADT (c) 2006 Elsevier
Last updated on Wednesday, March 04, 2020